Subtype
Malignant Peripheral Nervous System Neoplasm
CI-CAN-00001163Explore in graph →
20 active trials3 evidence items
- NCIt
- C4961
Loading cancer entity…
Subtype
CI-CAN-00001163Explore in graph →
Clinical trials
60 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (7)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02584647 | PLX3397 Plus Sirolimus in Unresectable Sarcoma and Malignant Peripheral Nerve Sheath Tumors(PLX3397) | terminated | Phase 1 / Phase 2 | 39 | Gulam ManjiOTHER | 1 | Mar 21, 2025 | clinicaltrials |
| NCT02601209 | Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma | terminated | Phase 1 / Phase 2 | 151 | National Cancer Institute (NCI)NIH | 1 | Aug 23, 2022 |
| NCT01418001 | Gemcitabine and Docetaxel in Combination With Pazopanib (Gem/Doce/Pzb) for the Neoadjuvant Treatment of Soft Tissue Sarcoma (STS) | terminated | Phase 1 / Phase 2 | 5 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jan 11, 2018 | clinicaltrials |
Data updated 22 days agoSource updated Mar 21, 2025source: clinicaltrials